Please assess the completion status of the following clinical trial:

Trial Title: Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Standard risk of Recipients (CR1 or CR 2 of AML/ALL before transplantation except Ph+ ALL and T-ALL) of allogeneic stem cell transplantation with myeloablative conditioning regimens~* Standard risk of Recipients: CR1 or CR 2 of AML/ALL before transplantation~* Ph+ ALL, AML with t(8;21) and T-ALL were excepted~* Patients were at least 60 days post-transplantation~* Bone marrow monitoring was still Complete Remission (CR) and minor residual disease (MRD) was negative~* 15 years of age or older~* No serious infection~Exclusion Criteria:~* Exposure to any other clinical trials prior to enrollment~* Active malignant disease relapse~* Active, uncontrolled infection~* Inability to comply with IL-2 treatment regimen

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Interleukin-2 (Type: EXPERIMENTAL): Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
- controlled group (Type: NO_INTERVENTION): controlled standard risk leukemia received regular transplantation without IL-2 intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).